Patents Assigned to Deutsches Krebsforschungszentrum
-
Patent number: 11964015Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.Type: GrantFiled: April 9, 2021Date of Patent: April 23, 2024Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERGInventors: Barbara Leuchs, Antonio Marchini, Jean Rommelaere, Assia Angelova, Dirk Jager, Wolfgang Wick, Michael Dahm
-
Patent number: 11964953Abstract: The present invention covers aminothiazole compounds of general formula (I), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGK?) regulated disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: September 14, 2022Date of Patent: April 23, 2024Assignees: Bayer Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Norbert Schmees, Ulrike Roehn, Dennis Kirchhoff, Kirstin Petersen, Mareike Grees, Nicolas Werbeck, Benjamin Bader, Rienk Offringa, Corinna Link
-
Patent number: 11931349Abstract: The present invention relates to a pharmaceutically compatible iron chelator or a prodrug thereof for use in treating and/or preventing cancer in a subject suspected or known to comprise hypoxic cancer cells, and use in treatment and/or prevention of a human papillomavirus (HPV) related lesion. The present invention further relates to a use of an iron chelator or prodrug thereof for inducing senescence in a cancer cell, preferably a hypoxic cancer cell; and to a method for inducing an irreversible proliferation arrest in cancer cells comprising a) contacting said cancer cells with an iron chelator or prodrug thereof and, thereby, b) inducing an irreversible proliferation arrest in said cancer cells.Type: GrantFiled: November 23, 2018Date of Patent: March 19, 2024Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Felix Hoppe-Seyler, Julia A. Braun, Karin Hoppe-Seyler
-
Patent number: 11899089Abstract: A phantom calibration body (110) for a method for determining at least one quantitative diffusion parameter extracted for characterization of a tissue being suspicious to a tumorous modification in magnetic resonance imaging is disclosed, wherein the phantom calibration body (110) is designed for being characterized during characterization of the tissue by the magnetic resonance imaging. Herein, the phantom calibration body (110) comprises a first compartment (112) having a first cross-section, the first compartment (112) being filled with a first solution comprising a calibration substance having a first concentration; and a second compartment (114) having a second cross-section, the second cross-section having at least two different partitions with differing diameters, wherein the second compartment (114) is filled with a second solution comprising the calibration substance having a second concentration, the second concentration differing from the first concentration.Type: GrantFiled: January 24, 2019Date of Patent: February 13, 2024Assignee: Deutsches KrebsforschungszentrumInventors: Sebastian Bickelhaupt, Tristan Anselm Kuder
-
Publication number: 20240036048Abstract: The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the biomarkers shown in Table 1 and comparing the said amount of the at least one biomarker with a reference, whereby pancreas cancer is to be diagnosed. The present invention also contemplates a method for identifying whether a subject is in need of a pancreas cancer therapy comprising the steps of the aforementioned methods and the further step of identifying a subject in need of a pancreas cancer therapy if said subject is to be diagnosed to suffer from pancreas cancer. Contemplated are, furthermore, diagnostic devices and kits for carrying out said methods.Type: ApplicationFiled: June 26, 2023Publication date: February 1, 2024Applicants: Deutsches Krebsforschungszentrum, Queen Mary University of LondonInventors: Christoph SCHRÖDER, Jörg HOHEISEL, Tatjana CRNOGORAC-JURCEVIC
-
Patent number: 11866495Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: January 29, 2020Date of Patent: January 9, 2024Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Marius Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
-
Publication number: 20240002845Abstract: The present invention provides the use of a CASP8AP2 antagonist in the prevention or treatment of cancer. Preferably, the antagonist reduces the viability of the cancer cells without significantly reducing the viability of normal cells in the subject to be treated. Further, methods of treatment and pharmaceutical compositions suitable in said methods are provided, as well.Type: ApplicationFiled: October 7, 2021Publication date: January 4, 2024Applicants: Albert-Ludwigs-Universitat Freiburg, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Sven Diederichs, Ksenia Myacheva
-
Publication number: 20240001153Abstract: A test system (124) for testing a system (110) for radiologic treatment. The test system (124) comprises: A • at least one anthropomorphic phantom (118) for simulating motion of at least one part of a human body (116); and B • a control device (122) for controlling the phantom (118), comprising •• a programmable logic controller (160), •• a plurality of controller nodes (162), •• a plurality of device controllers (164) configured for controlling the actuators (140), and •• at least one real-time bus interface (166) connecting the controller nodes (162) to the programmable logic controller (160) and to the device controllers (164). The programmable logic controller (160) is configured to act as a master device with respect to the controller nodes (162), specifically with respect to each of the controller nodes (162). The controller nodes (162) are configured to act as master devices with respect to the device controllers (164).Type: ApplicationFiled: December 3, 2021Publication date: January 4, 2024Applicant: Deutsches KrebsforschungszentrumInventors: Steffen Seeber, Carlos Murillo
-
Publication number: 20240000907Abstract: The invention is based on the finding that endoplasmic reticulum (ER) stress signalling is associated with the pathogenesis of liver disorders such fatty liver, cirrhosis and hepatocellular carcinoma (HCC), and others. The invention identifies novel targets for liver disease therapy which are involved in ER stress signalling, and thereby pertains to compounds and compositions for medical uses, screening approaches to identify therapeutics as well as diagnostic approaches for the identification of disorders or the stratification of certain liver disease patient groups. The invention also pertains to the use of immune checkpoint inhibitors in combination with the compounds or compositions and/or in the treatment of endoplasmic reticulum (ER) stress signalling induced liver cancers.Type: ApplicationFiled: November 12, 2021Publication date: January 4, 2024Applicant: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Mathias HEIKENWALDER, Xin LI, Pierluigi RAMADORI, Dirk HALLER
-
Patent number: 11862320Abstract: A control device (110) for controlling at least one collimator is disclosed, wherein the collimator has a plurality of parts being designed for collimating and shaping rays, wherein the rays are generated for treating a predefined body part of a patient, wherein the control device (110) comprises a programmable logic controller (112), a plurality of controller nodes (114), a plurality of device controllers (118), and a plurality of real-time bus interfaces (116). Herein, the programmable logic controller (112) is designated as a first master device (122) with respect to each of the controller nodes (114), wherein the programmable logic controller (112) is designed for superordinate control of the plurality of parts of the collimator.Type: GrantFiled: April 10, 2019Date of Patent: January 2, 2024Assignee: Deutsches KrebsforschungszentrumInventors: Steffen Seeber, Joao Graca
-
Patent number: 11851463Abstract: The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, e.g., which include an annexin core domain to mediate efficient antigen delivery and antigen presentation in order to induce an antigen-specific immune response and/or to treat or prevent infectious diseases and/or cancer.Type: GrantFiled: January 21, 2021Date of Patent: December 26, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Fatmire Bujupi, Peter Krammer, Heiko Weyd
-
Publication number: 20230406961Abstract: The present invention provides a novel bispecific anti-CD28 antibody format which is bivalent and comprises two CD28 binding sites, and at least one target binding site. The bispecific anti CD28 antibody of the invention is surprisingly advantageous due to its costimulatory activity which is strictly target cell restricted. The bispecific CD28 antibody of the invention is provided for use in the treatment of diseases either alone or in combination with a further bispecific antibody inducing a CD3/T cell receptor signal.Type: ApplicationFiled: November 3, 2021Publication date: December 21, 2023Applicants: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Eberhard Karls Universität TübingenInventors: Helmut SALIH, Gundram JUNG, Martin PFLÜGLER, Latifa ZEKRI, Timo MANZ
-
Patent number: 11836831Abstract: A method for training of a process for generating an image of an object from measurement data modified by scatter radiation. Individual sets of measured data are each made up of matrix elements. Each matrix element corresponds to an individual detector element that detects ionizing radiation. Signals measured by the individual detector elements in an energy bin are assigned as values for each matrix element. The individual sets of measured data and a template image are used as input for a procedure for determining a correction image for correcting a modification of the measured data by the scatter radiation. The preliminary image obtained using the individual sets of measured data is adjusted to the template. These steps are repeated until the deviation between the preliminary image and the template image is below a threshold. The procedure is used to generate the image of the object from the measurement data.Type: GrantFiled: January 29, 2021Date of Patent: December 5, 2023Assignee: Deutsches KrebsforschungszentrumInventors: Yannick Berker, Marc Kachelrieß
-
Patent number: 11806361Abstract: The present invention provides novel compounds that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with Non-Alcoholic Fatty Liver Disease (NAFLD). The invention provides these compounds for treating non-alcoholic steatohepatitis (NASH), a progressed stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and Hepatocellular Carcinoma (HCC). Further provided are pharmaceutical compositions, comprising the compounds of the invention, and methods for screening new NASH therapeuticals.Type: GrantFiled: March 31, 2021Date of Patent: November 7, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Mathias Heikenwälder, Lars Zender, Achim Weber
-
Patent number: 11806395Abstract: The present invention relates to a preparation comprising Epstein-Barr virus-like particles (EB-VLPs), said EB-VLPs being essentially free of Epstein Barr virus (EBV) DNA, wherein said EB-VLPs comprise a vaccination polypeptide comprising at least one peptide of an EBV tegument polypeptide and at least one immunogenic peptide; and to polynucleotides, host cells, and methods related thereto.Type: GrantFiled: October 11, 2019Date of Patent: November 7, 2023Assignee: Deutsches KrebsforschungszentrumInventors: Henri-Jacques Delecluse, Dwain Van Zyl
-
Publication number: 20230348462Abstract: The present invention relates to imidazo[4,5-c]quinoline compounds and to their use in the inhibition, regulation and/or modulation of signal transduction by ATM kinase and, in particular, for the treatment of ATM mediated diseases, especially cancer.Type: ApplicationFiled: May 1, 2023Publication date: November 2, 2023Applicants: Deutsches Krebsforschungszentrum, Eberhard Karls Universitat, Universitatsklinikum TubingenInventors: Stefan Laufer, Michael Forster, Teodor Dimitrov, Lars Zender, Athina Moschopoulou
-
Patent number: 11802285Abstract: The present invention relates to a compound selectively binding to a sensory receptor or selectively altering the expression of a sensory receptor for use in a method for treating or preventing a disease associated with a pathologic cellular cytotoxic T cell (CTL) response. Further, the invention relates to means for detecting a sensory receptor for use in a method for diagnosing cellular resistance against CTL response in a patient. The invention further embraces a method for determining the resistance of a cell against a CTL response in vitro and to a method for identifying agents that influence the response of cells to CTLs.Type: GrantFiled: September 6, 2019Date of Patent: October 31, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Philipp Beckhove, Michael Boutros, Nisit Khandelwal, Marco Breinig
-
Publication number: 20230341406Abstract: The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monomer of human collagen 18 and a Fc domain of an immunoglobulin. The invention also relates to a fusion protein comprising: a) an endostatin peptide or endostatin-derived peptide and b) the RGD motif and/or PHSRN motif of Fibronectin. The invention further relates to a kit comprising the protein oligomer or fusion proteins of the invention.Type: ApplicationFiled: October 14, 2022Publication date: October 26, 2023Applicant: Deutsches KrebsforschungszentrumInventors: Tong-Young LEE, Amir ABDOLLAHI, Kashi JAVAHERIAN
-
Patent number: 11795164Abstract: The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1): in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 12, 2022Date of Patent: October 24, 2023Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches KrebsforschungszentrumInventors: Ilona Gutcher, Norbert Schmees, Lars Röse, Benjamin Bader, Christina Kober, Rafael Carretero, Detlef Stöckigt, Horst Irlbacher, Michael Platten
-
Patent number: 11773164Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: January 29, 2020Date of Patent: October 3, 2023Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge